2024
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations
Gebrael G, Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor–based Combinations. European Urology Focus 2024, 10: 812-817. PMID: 38580524, DOI: 10.1016/j.euf.2024.03.006.Peer-Reviewed Original ResearchTime to treatment failureDisease control rateRenal cell carcinomaSynchronous metastasesMetachronous metastasesOverall survivalMetachronous metastatic renal cell carcinomaMedian time to treatment failureICI-based combination therapyAssociated with worse OSMetastatic renal cell carcinomaFirst-line immunotherapyICI-based combinationsRenal cell carcinoma diagnosisDiagnosis of kidney cancerHypothesis-generating studyMedian OSMetachronous groupPoor OSTreatment failureCombination therapyMetastasis onsetCell carcinomaSurvival outcomesClinical outcomes
2023
Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
Meza L, Li X, Zengin Z, Sayegh N, Ebrahimi H, Tripathi N, Castro D, Mercier B, Barragan-Carrillo R, Li H, Chehrazi-Raffle A, Swami U, Tripathi A, Agarwal N, Maughan B, Pal S. Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations. The Oncologist 2023, 28: s9-s10. PMCID: PMC10445590, DOI: 10.1093/oncolo/oyad216.014.Peer-Reviewed Original ResearchDisease control rateFirst-line ICIImmune checkpoint inhibitorsOverall survivalTime of presentationSynchronous diseaseTreatment failureRenal cell carcinomaMetachronous diseaseMetastatic diseaseRCC diagnosisFirst-line immune checkpoint inhibitorsMetastatic renal cell carcinoma patientsMultivariable Cox proportional hazards modelsLower disease control rateNon-clear cell histologyMetastatic renal cell carcinomaRenal cell carcinoma patientsCox proportional hazards modelIMDC risk scoresInitial RCC diagnosisSynchronous metastatic diseaseMedian overall survivalMedian TTFFirst-line treatmentAssociation Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'Brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Hsu J, Li X, Agarwal N, Pal S. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer 2023, 21: 530-536. PMID: 37495481, DOI: 10.1016/j.clgc.2023.06.004.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaObjective response rateTreatment failureRenal cell carcinomaHazard ratioOverall survivalCell carcinomaMultivariate analysisHigh Cut-OffNivolumab/ipilimumabProspective Randomized StudyBaseline characteristicsRandomized studyClinical outcomesMedian timePreclinical evidenceUnivariate analysisPatientsResponse rateImmune systemInfusion timeStatistical significanceOutcomesCarcinomaInfusionAssociation between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).
Dizman N, Govindarajan A, Zengin Z, Meza L, Tripathi N, Sayegh N, Castro D, Chan E, Lee K, Prajapati S, Feng M, Loo V, Pace M, O'brien S, Bailey E, Barragan-Carrillo R, Chehrazi-Raffle A, Li X, Agarwal N, Pal S. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2023, 41: 678-678. DOI: 10.1200/jco.2023.41.6_suppl.678.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaMedian overall survivalOverall survivalHazard ratioPotential confoundersMedian TTFDisease outcomeMultivariate analysisCox proportional hazards modelEfficacy of ICIsObjective response ratePoor-risk diseaseProgression-free survivalSecond-line treatmentClear cell histologyRenal cell carcinomaProportional hazards modelBaseline characteristicsFree survivalCell histologyMedian ageRisk diseaseTreatment failureEntire cohortCell carcinoma
2022
CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Navani V, Wells J, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Meza L, Pal S, Donskov F, Beuselinck B, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Clinical Genitourinary Cancer 2022, 21: 106.e1-106.e8. PMID: 35945133, DOI: 10.1016/j.clgc.2022.07.008.Peer-Reviewed Original ResearchConceptsInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabOverall survivalTreatment failureAdvanced renal cell carcinomaActivity of cabozantinibClinically meaningful activityMedian TTFEffects of cabozantinibGrowth factor inhibitorsRenal cell carcinomaMultivariate Cox regressionMedian OSRetrospective observational naturePoor riskCell carcinomaFactor inhibitorsCabozantinibCox regressionResponse ratePatientsOverall populationObservational natureVEGFiMonthsOutcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy
Graham J, Wells J, Dudani S, Gan C, Donskov F, Lee J, Kollmannsberger C, Meza L, Beuselinck B, Hansen A, North S, Bjarnason G, Sayegh N, Kanesvaran R, Wood L, Hotte S, McKay R, Choueiri T, Heng D. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal Of Cancer 2022, 171: 124-132. PMID: 35717820, DOI: 10.1016/j.ejca.2022.05.002.Peer-Reviewed Original ResearchConceptsInternational Metastatic RCC Database ConsortiumImmune checkpoint inhibitor groupImmune checkpoint inhibitorsVascular endothelial growth factorICI-based therapyObjective response rateVascular endothelial growth factor groupMammalian target of rapamycinClear-cell renal cell carcinomaFirst-line therapyOutcomes of patientsRenal cell carcinomaTreatment failureOverall survivalInhibitor monotherapyCell carcinomaFirst-lineAdvanced non-clear cell renal cell carcinomaInternational Metastatic RCC Database Consortium risk groupMammalian target of rapamycin-targeted therapiesMetastatic clear-cell renal cell carcinomaNon-clear cell renal cell carcinomaNon-clear cell RCCAssociated with improved OSMedian TTFCABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Navani V, Wells C, Boyne D, Cheung W, Brenner D, McGregor B, Labaki C, Schmidt A, McKay R, Pal S, Meza L, Donskov F, Beuselinck B, Ernst M, Otiato M, Ludwig L, Powles T, Szabados B, Choueiri T, Heng D. CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Journal Of Clinical Oncology 2022, 40: 318-318. DOI: 10.1200/jco.2022.40.6_suppl.318.Peer-Reviewed Original ResearchInternational Metastatic Renal Cell Carcinoma Database ConsortiumIpilimumab-nivolumabTreatment failureOverall survivalInternational Metastatic Renal Cell Carcinoma Database Consortium criteriaInternational Metastatic Renal Cell Carcinoma Database Consortium risk groupAdvanced renal cell carcinomaResponse rateActivity of cabozantinibClinically meaningful activityRenal cell carcinomaEndothelial growth factorCell histologySarcomatoid componentBone metastasesVEGF inhibitorsPoor riskCell carcinomaCabozantinibHazard ratioRisk groupsPatientsGrowth factorTherapyEarly lines
2021
The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).
Ernst M, Alaiwi S, Dizman N, Labaki C, Nuzzo P, Adib E, Schmidt A, Meza L, Gan C, Wells J, Bakouny Z, Pal S, Choueiri T, Heng D, Dudani S. The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT). Journal Of Clinical Oncology 2021, 39: 4552-4552. DOI: 10.1200/jco.2021.39.15_suppl.4552.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaImmune checkpoint inhibitorsOverall survivalABS exposureClinical outcomesTreatment failureResponse rateMultivariable analysisIndependent associationRisk factorsAdministration of AbFourth-line settingIMDC risk factorsIMDC risk scoresPoor-risk diseaseTreatment linesMultivariable Cox regressionInferior clinical outcomesInferior overall survivalIndependent prognostic markerRenal cell carcinomaSignificant independent associationOutcomes of interestIMDC criteriaCheckpoint inhibitors